RESEARCHER PROFILE
Dr Katharina Richter,
University of Adelaide
Filmed November 2023
Dr Katharina Richter is a visionary leader in MedTech, acclaimed for innovation and gender diversity. With over 40 awards to her name, including MIT Innovator Under 35 Asia-Pacific, and Prime Minister’s Prize for New Innovator finalist, she has shattered barriers as an entrepreneur, scientist, and ‘superbug slayer.’ Katharina’s groundbreaking work in combating antibiotic-resistant bacteria has resulted in 6 innovative treatments, 3 of which are patented, offering hope against deadly infections.
Katharina champions gender diversity, serving as a role model for aspiring female leaders. Her international impact is undeniable, as she elevates Australian MedTech on the global stage through panels, collaborations and media engagements. Katharina’s leadership extends to various committees and organisations, where she nurtures the next generation of MedTech
leaders through mentorship and career-development initiatives. Her remarkable journey showcases her as a true pioneer, leaving an indelible mark on both the MedTech industry and the advancement of women within it.
-
Treatment pathways for chronic plantar heel pain
Jason Rogers is a Tasmanian physiotherapist clinician-researcher with a longstanding interest in improving musculoskeletal foot and ankle conditions. He completed his PhD at the Menzies Institute for Medical Research at the University of Tasmania in 2022 investigating the clinical and imaging factors associated with a common foot complaint known as chronic plantar heel pain.
-
Dr Nischal Sahai
RESEARCH IN DEVICE TRIALS, VACCINE STUDIES, ORAL MEDICATIONS, INJECTABLES & INFUSIONS.
@ CLINICAL TRIAL CENTRE, UNIVERSITY OF THE SUNSHINE COAST
QUEENSLAND, AUSTRALIA -
Oral administration of insulin for Type 1 Diabetes
Huiwen Pang is a 3rd year PhD candidate in the Australian Institute for Bioengineering and Nanotechnology, University of Queensland, focusing on biomedical health research. Prior to commencing his PhD, Huiwen studied animal genetics in his Masters degree at Huazhong Agriculture University in China.
People with diabetes, especially Type 1 diabetes, largely rely on the insulin injections or insulin pumps to control their high blood glucose levels, which is painful and has a high risk of infections.
Huiwen Pang is conducting research on nano-based drug formulations for Type 1 diabetes treatment, with a focus on using nanomaterials to load insulin for oral administration and employing anti-apoptotic and anti-inflammatory approaches to mitigate damage to beta cells.
